Top

Published in:

01-12-2014 | Editorial

A revival for immunoglobulin therapy in septic shock?

Authors: Julien Textoris, Thierry Calandra, Frédéric Pène

Published in: Intensive Care Medicine | Issue 12/2014

Excerpt

As of 13 September 2014, World Sepsis Day, sepsis remains a leading cause of death worldwide. Over the last decade, the implementation of guidelines or bundles has had a major impact on the management of sepsis patients, stressing the need for prompt diagnosis and therapy including (1) early administration of antibiotics and source control, (2) hemodynamic resuscitation, and (3) prevention and management of organ failures. Besides antimicrobial therapy and supportive care, no immunomodulatory strategy has yielded clear-cut and reproducible results in terms of improved survival [1]. …

Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862–874PubMedCrossRef

Gatterre P, Oualha M, Dupic L, Iserin F, Bodemer C, Lesage F, Hubert P (2012) Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med 38:872–878PubMedCrossRef

Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13:176–189PubMedCrossRef

Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M (2012) Bench-to-bedside review: immunoglobulin therapy for sepsis—biological plausibility from a critical care perspective. Crit Care 16:206PubMedCentralPubMedCrossRef

Jayasekera JP, Moseman EA, Carroll MC (2007) Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 81:3487–3494PubMedCentralPubMedCrossRef

Kinoshita M, Shinomiya N, Ono S, Tsujimoto H, Kawabata T, Matsumoto A, Hiraide H, Seki S (2006) Restoration of natural IgM production from liver B cells by exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas aeruginosa. J Immunol 177:4627–4635PubMedCrossRef

Ghumra A, Semblat JP, McIntosh RS, Raza A, Rasmussen IB, Braathen R, Johansen FE, Sandlie I, Mongini PK, Rowe JA, Pleass RJ (2008) Identification of residues in the Cmu4 domain of polymeric IgM essential for interaction with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). J Immunol 181:1988–2000PubMedCentralPubMedCrossRef

Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M (2005) Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 35:252–260PubMedCrossRef

Notley CA, Brown MA, Wright GP, Ehrenstein MR (2011) Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J Immunol 186:4967–4972PubMedCrossRef

10.

Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 9:CD001090

11.

Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P (2011) Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med 155:39–51PubMedCrossRef

12.

Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P (2014) Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA 312:623–630PubMedCrossRef

13.

Gelfand EW (2006) Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 6:592–599PubMedCrossRef

14.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228PubMedCrossRef

15.

Cavazzuti I, Serafini G, Busani S, Rinaldi L, Biagioni E, Buoncristiano M, Girardis M (2014) Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med. doi:10.1007/s00134-014-3474-6 PubMed

16.

Venet F, Gebeile R, Bancel J, Guignant C, Poitevin-Later F, Malcus C, Lepape A, Monneret G (2011) Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol 11:2086–2090PubMedCrossRef

Title: A revival for immunoglobulin therapy in septic shock?
Authors: Julien Textoris
Thierry Calandra
Frédéric Pène
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 12/2014
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-014-3506-2

At a glance: The STEP trials

Springer Medicine

A revival for immunoglobulin therapy in septic shock?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2014

What’s new: the management of acute right ventricular decompensation of chronic pulmonary hypertension

Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: con

Understanding organ dysfunction in Ebola virus disease

Erratum to: Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period

The definition of starting point for evaluation of timely adequate antifungal therapy

Risk of bloodstream infection in children admitted to paediatric intensive care units in England and Wales following emergency inter-hospital transfer